0 0

Government Restriction: Chlorpheniramine-Phenylephrine FDCs Prohibited for Children Below 4 Years – Regulatory Alert

Government Restriction: Chlorpheniramine-Phenylephrine FDCs Prohibited for Children Below 4 Years – Regulatory Alert
Spread the love

Regulatory Alert: Government Restricts FDCs for Children Below 4 Years

Government Restrictions on Chlorpheniramine Maleate & Phenylephrine Hydrochloride FDCs (2025)

The Government of India and the Ministry of Health and Family Welfare have issued a critical regulatory update regarding Fixed Dose Combinations (FDCs) used in pediatric care. Effective immediately, medicines containing the combination of Chlorpheniramine Maleate and Phenylephrine Hydrochloride are restricted for use in children below a certain age group due to safety concerns.

Regulatory Overview & Summary

Key Information Details
Affected Combination Chlorpheniramine Maleate + Phenylephrine Hydrochloride
Age Restriction Strictly prohibited for children below 4 years of age
Regulatory Body Drugs Technical Advisory Board (DTAB) & Expert Committee
Legal Provision Section 26A of the Drugs and Cosmetics Act, 1940
Purpose To improve pediatric medicine safety and prevent inappropriate use

Clinical Profile of the Ingredients

Active Ingredient Pharmacological Category Common Therapeutic Use
Chlorpheniramine Maleate Antihistamine (H1 Blocker) Relief from watery eyes, sneezing, and runny nose (Allergy symptoms).
Phenylephrine Hydrochloride Decongestant Temporary relief from nasal congestion and sinus pressure.
FDC Combined Form Cough & Cold Preparation Commonly used in syrups and drops for common cold symptoms.

Mandatory Labeling Requirements

“Fixed Dose Combination shall not be used in children below four years of age.”
Manufacturers must ensure the above warning is prominently displayed on:
  • The primary medicine label
  • The Package Insert (PI)
  • All Promotional Literature issued to doctors/pharmacists

Guidelines for Pharmacists & Healthcare Professionals

Stakeholder Mandatory Action Items
Pharmacists Check formulation composition before dispensing; Counsel parents on age limits.
Paediatricians Prescribe safer alternatives for infants and toddlers below 4 years.
Manufacturers Update all packaging materials as per S.O. 1717(E) notification standards.
Parents/Caregivers Avoid self-medication and always check the active ingredient list.

Historical & Legal Context

Notification Timeline
Previous Restriction Date 15 April 2025 (via Notification S.O. 1717(E))
Current Update Scope Extends the requirement to ALL formulations containing these two ingredients.
Effective Date From the date of publication in the Official Gazette.
Disclaimer: This post is for educational purposes for pharmacy students and professionals. Always refer to the latest government gazette for official legal compliance.

Spread the love
Prev post Eli Lilly Launches Foundayo (Orforglipron) in UK: First Oral GLP-1 for Weight Loss

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Registration Form

Login

This will close in 0 seconds

© 2026 Pharmacy India. All Rights Reserved.
WhatsApp Telegram